- Home
- WSBF vs EDIT Comparison
WSBF vs EDIT Comparison
Compare WSBF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- EDIT
- Stock Information
- Founded
- WSBF 1921
- EDIT 2013
- Country
- WSBF United States
- EDIT United States
- Employees
- WSBF N/A
- EDIT N/A
- Industry
- WSBF Savings Institutions
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WSBF Finance
- EDIT Health Care
- Exchange
- WSBF Nasdaq
- EDIT Nasdaq
- Market Cap
- WSBF 299.6M
- EDIT 327.0M
- IPO Year
- WSBF N/A
- EDIT 2016
- Fundamental
- Price
- WSBF $14.96
- EDIT $3.31
- Analyst Decision
- WSBF
- EDIT Buy
- Analyst Count
- WSBF 0
- EDIT 10
- Target Price
- WSBF N/A
- EDIT $10.50
- AVG Volume (30 Days)
- WSBF 40.9K
- EDIT 2.0M
- Earning Date
- WSBF 10-22-2024
- EDIT 11-01-2024
- Dividend Yield
- WSBF 4.12%
- EDIT N/A
- EPS Growth
- WSBF 4.58
- EDIT N/A
- EPS
- WSBF 0.62
- EDIT N/A
- Revenue
- WSBF $132,560,000.00
- EDIT $67,034,000.00
- Revenue This Year
- WSBF N/A
- EDIT N/A
- Revenue Next Year
- WSBF N/A
- EDIT N/A
- P/E Ratio
- WSBF $23.89
- EDIT N/A
- Revenue Growth
- WSBF N/A
- EDIT 247.04
- 52 Week Low
- WSBF $9.62
- EDIT $2.91
- 52 Week High
- WSBF $16.36
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- WSBF 56.85
- EDIT 45.17
- Support Level
- WSBF $13.52
- EDIT $2.91
- Resistance Level
- WSBF $14.62
- EDIT $3.55
- Average True Range (ATR)
- WSBF 0.34
- EDIT 0.19
- MACD
- WSBF 0.05
- EDIT 0.04
- Stochastic Oscillator
- WSBF 99.33
- EDIT 56.74
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, It operates in two segments: Community Banking and Mortgage Banking. The community banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the community banking segment.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.